Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.71 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | TEK | Q02763 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.42 |
| ▸ | PI4KA | P42356 | 3/20 | 0.40 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.40 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | AHCY | P23526 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5801729 | 0.83 | ADORA2A (1.00) | ADORA2AADORA1EGFRSRCKDR | |
| SCHEMBL1665301 | 0.83 | ADORA2A (0.69) | ADORA2AADORA1EGFRSRCKDR | |
| SCHEMBL4815870 | 0.80 | ADORA2A (0.71) | ADORA2AADORA1EGFRSRCKDR | |
| SCHEMBL9778803 | 0.79 | ADORA2A (0.63) | ADORA2AADORA1EGFRSRCKDR | |
| SCHEMBL8584781 | 0.76 | ADORA2A (0.64) | ADORA2AADORA1EGFRSRCKDR | |
| SCHEMBL4343213 | 0.76 | ADORA2A (0.60) | ADORA2AADORA1EGFRSRCKDR | |
| SCHEMBL4541360 | 0.75 | ADORA2A (0.62) | ADORA2AADORA1EGFRSRCKDR | |
| SCHEMBL6661754 | 0.74 | ADORA2A (0.56) | ADORA2AADORA1EGFRSRCKDR | |
| Hydrochloric Acid SCHEMBL9778362 | 0.74 | ADORA2A (0.75) | ADORA2AADORA1KDRADORA2B | |
| Hydrochloric Acid SCHEMBL9778392 | 0.74 | ADORA2A (0.75) | ADORA2AADORA1KDRADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3670523-B1 | 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND THEIR USE IN METHODS FOR NUCLEIC ACID SEQUENCING | AGILENT TECHNOLOGIES INC (US) | 2021-08-11 | — | — | EP | disclosed |
| US-11001886-B2 | 3′-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing | AGILENT TECHNOLOGIES, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| EP-3670523-A1 | 5-METHOXY. 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | Agilent Technologies, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-2755984-B1 | 5-METHOXY. 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | AGILENT TECHNOLOGIES INC (US) | 2020-02-12 | — | — | EP | disclosed |
| US-20190127790-A1 | 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2019-05-02 | — | — | US | disclosed |
| US-10041115-B2 | 3′-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing | LASERGEN, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| EP-2307565-B1 | REVERSIBLE NUCLEOSIDES AND NUCLEOTIDES TERMINATORS AND THEIR USE IN DNA SEQUENCING | LASERGEN INC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170327886-A1 | 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | LASERGEN, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| US-9689035-B2 | 3′-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing | LASERGEN, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160369336-A1 | 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | LASERGEN, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| EP-2755984-A1 | 5-METHOXY. 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | Lasergen, Inc. (US) | 2014-07-23 | — | — | EP | disclosed |
| US-20140051848-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2014-02-20 | — | — | US | disclosed |
| US-8497360-B2 | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20130122489-A1 | 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2013-05-16 | — | — | US | disclosed |
| WO-2013040257-A1 | 5-METHOXY. 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | LASERGEN, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
| US-20130035237-A1 | Nucleotides and Nucleosides and Methods for their Use in DNA Sequencing | AGILENT TECHNOLOGIES, INC. | 2013-02-07 | — | — | US | disclosed |
| US-8148503-B2 | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| EP-2307565-A2 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | Lasergen, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100041041-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2010-02-18 | — | — | US | disclosed |
| WO-2009152353-A2 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041041-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | UNG, NT5C2, NT5E | ADORA2A 274/4885ADORA1 251/4885EGFR 2738/4885 |
| US-20190127790-A1 | 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | RNGTT, NT5C3B, NSUN2 | ADORA2A 1117/4885ADORA1 1196/4885EGFR 3934/4885 |
| US-10041115-B2 | 3′-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing | RNGTT, NT5C3B, NSUN2 | ADORA2A 1058/4885ADORA1 1143/4885EGFR 3893/4885 |
| US-11001886-B2 | 3′-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing | RNGTT, NT5C3B, NSUN2 | ADORA2A 1058/4885ADORA1 1143/4885EGFR 3893/4885 |
| US-20170327886-A1 | 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | RNGTT, NT5C3B, NSUN2 | ADORA2A 1117/4885ADORA1 1196/4885EGFR 3934/4885 |
| US-20160369336-A1 | 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | RNGTT, NT5C3B, NSUN2 | ADORA2A 1117/4885ADORA1 1196/4885EGFR 3934/4885 |
| US-20130035237-A1 | Nucleotides and Nucleosides and Methods for their Use in DNA Sequencing | UNG, NT5C2, NT5E | ADORA2A 274/4885ADORA1 251/4885EGFR 2738/4885 |
| US-20130122489-A1 | 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING | RNGTT, NT5C3B, NSUN2 | ADORA2A 1117/4885ADORA1 1196/4885EGFR 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.